Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 9;24(5):789. doi: 10.3892/mmr.2021.12429

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Zhang et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 1. — Clinical significance of INHBA in non-small cell lung cancer. (A) IHC scores of INHBA in 238 NSCLC tissues were significantly higher compared with those in 30 cases of normal lung tissues. (B) Western blotting of INHBA expression levels in T tissues and in matched, adjacent NT tissues. (C) Semi-quantification of western blotting of 24 paired tissue samples. INHBA protein expression levels were significantly higher in T samples compared with those in NT samples. (D) mRNA expression levels of INHBA were significantly higher in T samples compared with those in NT samples. (E) Representative cases showed that INHBA expression was increased in MN tissues compared with in paired PT tissues (original magnification, ×40 or ×200). (F) Based on the scores from immunohistochemistry, the abundance of INHBA was elevated in MN tissues compared with in PT tissues (n=30). (G) Kaplan-Meier curve for overall survival in 238 patients. Higher INHBA expression levels in NSCLC, based on immunohistochemistry scores, were associated with poorer overall survival. (H) Kaplan-Meier curve for disease-free survival. Higher INHBA expression levels in NSCLC were associated with poorer disease-free survival. **P<0.01, ***P<0.001. INHBA, inhibin βA; IHC, immunohistochemistry; NSCLC, non-small cell lung cancer; T, tumor; NT, non-tumor; MN, metastatic nodule; PT, primary tumor.